79 related articles for article (PubMed ID: 14671642)
1. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.
Rose C; Dupire S; Roche-Lestienne C; Grardel N; Bourgeois E; Cambier N; Preudhomme C
Leukemia; 2004 Feb; 18(2):354-5. PubMed ID: 14671642
[No Abstract] [Full Text] [Related]
2. Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission.
Cervetti G; Galimberti S; Carulli G; Petrini M
Leuk Res; 2005 Sep; 29(9):1097-8. PubMed ID: 16038739
[No Abstract] [Full Text] [Related]
3. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
Musto P; Perla G; Minervini MM; Carella AM; Coco FL; Catalano G
Leuk Res; 2004 Jul; 28(7):773-4. PubMed ID: 15158099
[No Abstract] [Full Text] [Related]
4. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
Sørensen AL; Larsen H
Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.
Onitilo AA; Kio EA; Singh AK; Lazarchick J
Leuk Lymphoma; 2005 Nov; 46(11):1667-70. PubMed ID: 16236620
[TBL] [Abstract][Full Text] [Related]
7. [Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome].
Nemchenko IS; Khoroshko ND; Turkina AG; Vinogradova OIu; Sokolova MA; Abakumov EM; Semenova EA; Zakharova AV; Domracheva EV
Ter Arkh; 2004; 76(7):87-90. PubMed ID: 15379136
[No Abstract] [Full Text] [Related]
8. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate.
Christoforidou A; Kotsianidis I; Margaritis D; Anastasiadis A; Douvali E; Tsatalas C
Am J Hematol; 2012 Jan; 87(1):131-2. PubMed ID: 21919038
[No Abstract] [Full Text] [Related]
9. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Garg A; Duggal L; Aggarwal S; Jain N
J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis.
Ishii Y; Ito Y; Kuriyama Y; Tauchi T; Ohyashiki K
Leuk Res; 2004 May; 28 Suppl 1():S79-80. PubMed ID: 15036947
[No Abstract] [Full Text] [Related]
11. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
[TBL] [Abstract][Full Text] [Related]
12. Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib.
Hus M; Helbig G; Cioch M; Szczepanska-Szerej H; Wieczorek P; Woźniak M; Kozinska J; Morawska M; Dmoszynska A; Kyrcz-Krzemien S; Kata D
Leuk Res; 2011 Mar; 35(3):e15-7. PubMed ID: 21093052
[No Abstract] [Full Text] [Related]
13. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
14. Reader's response to "Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate".
Shinkarow JW
MedGenMed; 2007; 9(1):39. PubMed ID: 17441290
[No Abstract] [Full Text] [Related]
15. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
Payne SM; Kovacs MJ
Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
[TBL] [Abstract][Full Text] [Related]
17. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
18. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
19. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.
Lange T; Bumm T; Mueller M; Otto S; Al-Ali HK; Grommisch L; Musiol S; Franke C; Krahl R; Niederwieser D; Deininger MW
Leukemia; 2005 Jul; 19(7):1262-5. PubMed ID: 15858618
[No Abstract] [Full Text] [Related]
20. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
